FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283997> ?p ?o ?g. }

• W4379283997 endingPage "3574" @default.
• W4379283997 startingPage "3574" @default.
• W4379283997 abstract "3574 Background: Meta-analysis of five randomized intensification trials in mCRC demonstrated an overall survival (OS) benefit of triplet chemotherapy (5FU/leucovorin, oxaliplatin, irinotecan) plus bevacizumab (Triplet/Bev) compared to doublet chemotherapy plus bevacizumab (Doublet/Bev) (HR 0.81). Guidelines recommend first-line Triplet/Bev for patients with excellent performance status and normal organ function who can withstand increased toxicity, but such patients are less represented in the real world. In this retrospective cohort study, we examine the real-world effectiveness of Triplet/Bev compared to Doublet/Bev in the U.S. Methods: We used the nationwide Flatiron Health electronic health record-derived database, comprising de-identified patient-level structured and unstructured data curated via technology-enabled abstraction from ~ 280 cancer clinics. Included were mCRC patients treated with first-line Triplet/Bev or Doublet/Bev between 10/23/14 and 10/31/22. OS by treatment was assessed using the Kaplan Meier method and adjustment for confounding variables was performed using Cox proportional hazards modeling with stabilized inverse probability of treatment weighting (IPTW). Pre-specified confounding variables included age, gender, race/ethnicity, year of metastatic diagnosis, health insurance, practice setting, KRAS/NRAS/BRAF mutation status, MMR/MSI status, synchronous/metachronous metastases, primary tumor sidedness, CEA, renal dysfunction, hepatic dysfunction, and ECOG performance status. Missing data were imputed using multiple imputation with chained equations. Results: Among 10,016 patients, 391 (3.9%) received Triplet/Bev and 9,625 (96.1%) received Doublet/Bev. Patients who received Triplet/Bev were younger (median age 52 vs 63 years) and were more likely to be treated at academic practices (27% vs 8%), to have synchronous metastatic disease (83% vs 65%), and to have KRAS/NRAS/BRAF wild-type disease (30% vs 17%). In the univariate analysis, median OS was 30.0 months (95% CI 24.7 – 34.7) in the Triplet/Bev cohort versus 23.4 months (95% CI 22.8 – 24.1) in the Doublet/Bev cohort (HR 0.73; 95% CI 0.62 – 0.85; p < 0.001). In Cox proportional hazards modeling with IPTW, there was no significant difference in hazard of death between Triplet/Bev and Doublet/Bev (HR 0.92; 95% CI 0.75 – 1.12; p = 0.4). Conclusions: In this large, national, real-world population of patients with mCRC, first-line treatment with Triplet/Bev was not associated with improved survival compared to Doublet/Bev after accounting for differences in baseline patient characteristics. The benefit to Triplet/Bev observed in randomized trials does not translate well to a more heterogeneous, real-world population. Sub-group analyses including by age, tumor sidedness, KRAS/NRAS/BRAF status, and baseline CEA level will be performed." @default.
• W4379283997 created "2023-06-05" @default.
• W4379283997 creator A5007235827 @default.
• W4379283997 creator A5042029338 @default.
• W4379283997 creator A5045517963 @default.
• W4379283997 creator A5055266545 @default.
• W4379283997 date "2023-06-01" @default.
• W4379283997 modified "2023-10-17" @default.
• W4379283997 title "Real-world comparison of triplet- versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC)." @default.
• W4379283997 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.3574" @default.
• W4379283997 hasPublicationYear "2023" @default.
• W4379283997 type Work @default.
• W4379283997 citedByCount "0" @default.
• W4379283997 crossrefType "journal-article" @default.
• W4379283997 hasAuthorship W4379283997A5007235827 @default.
• W4379283997 hasAuthorship W4379283997A5042029338 @default.
• W4379283997 hasAuthorship W4379283997A5045517963 @default.
• W4379283997 hasAuthorship W4379283997A5055266545 @default.
• W4379283997 hasConcept C121608353 @default.
• W4379283997 hasConcept C126322002 @default.
• W4379283997 hasConcept C143998085 @default.
• W4379283997 hasConcept C167135981 @default.
• W4379283997 hasConcept C207103383 @default.
• W4379283997 hasConcept C2776694085 @default.
• W4379283997 hasConcept C2776705615 @default.
• W4379283997 hasConcept C2776907518 @default.
• W4379283997 hasConcept C2777802072 @default.
• W4379283997 hasConcept C2779998722 @default.
• W4379283997 hasConcept C2780259306 @default.
• W4379283997 hasConcept C2780962732 @default.
• W4379283997 hasConcept C2781187634 @default.
• W4379283997 hasConcept C44249647 @default.
• W4379283997 hasConcept C50382708 @default.
• W4379283997 hasConcept C526805850 @default.
• W4379283997 hasConcept C71924100 @default.
• W4379283997 hasConceptScore W4379283997C121608353 @default.
• W4379283997 hasConceptScore W4379283997C126322002 @default.
• W4379283997 hasConceptScore W4379283997C143998085 @default.
• W4379283997 hasConceptScore W4379283997C167135981 @default.
• W4379283997 hasConceptScore W4379283997C207103383 @default.
• W4379283997 hasConceptScore W4379283997C2776694085 @default.
• W4379283997 hasConceptScore W4379283997C2776705615 @default.
• W4379283997 hasConceptScore W4379283997C2776907518 @default.
• W4379283997 hasConceptScore W4379283997C2777802072 @default.
• W4379283997 hasConceptScore W4379283997C2779998722 @default.
• W4379283997 hasConceptScore W4379283997C2780259306 @default.
• W4379283997 hasConceptScore W4379283997C2780962732 @default.
• W4379283997 hasConceptScore W4379283997C2781187634 @default.
• W4379283997 hasConceptScore W4379283997C44249647 @default.
• W4379283997 hasConceptScore W4379283997C50382708 @default.
• W4379283997 hasConceptScore W4379283997C526805850 @default.
• W4379283997 hasConceptScore W4379283997C71924100 @default.
• W4379283997 hasIssue "16_suppl" @default.
• W4379283997 hasLocation W43792839971 @default.
• W4379283997 hasOpenAccess W4379283997 @default.
• W4379283997 hasPrimaryLocation W43792839971 @default.
• W4379283997 hasRelatedWork W1963973664 @default.
• W4379283997 hasRelatedWork W2010928484 @default.
• W4379283997 hasRelatedWork W2014795358 @default.
• W4379283997 hasRelatedWork W2051540233 @default.
• W4379283997 hasRelatedWork W2071471252 @default.
• W4379283997 hasRelatedWork W2591743724 @default.
• W4379283997 hasRelatedWork W2599866838 @default.
• W4379283997 hasRelatedWork W2617055067 @default.
• W4379283997 hasRelatedWork W2766337786 @default.
• W4379283997 hasRelatedWork W2939662662 @default.
• W4379283997 hasVolume "41" @default.
• W4379283997 isParatext "false" @default.
• W4379283997 isRetracted "false" @default.
• W4379283997 workType "article" @default.